GlassScriptPhysician profile
Linda Slade
NPI 1477526606
$2,017.93
in general payments reported to CMS, 2019-2025
20 companies · $643 in 2025
The $643 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.30 · 2020: $92.64 · 2021: $282 · 2022: $392 · 2023: $334 · 2024: $223 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.37 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $304.11 | 2023-2025 | Syfovre |
| Allergan, INC. | $262.38 | 2021-2022 | |
| Dompe US, INC. | $234.27 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $178.17 | 2020-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $157.53 | 2021 | |
| Alexion Pharmaceuticals, INC. | $140.09 | 2024-2025 | Ultomiris |
| Lkc Technologies, INC. | $101.15 | 2025 | |
| Bausch & Lomb Americas INC. | $82.50 | 2023-2025 | Miebo, Xiidra |
| Glaukos Corporation | $78.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $69.33 | 2022-2023 | |
| Amgen INC. | $59.81 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $57.81 | 2022 | |
| Rxsight INC | $56.55 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Astellas Pharma US INC | $54.14 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $44.80 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $38.98 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.20 | 2019 | |
| Alcon Vision LLC | $25.39 | 2022 | |
| Biotissue Holdings INC. | $22.00 | 2025 | |
| Shire North American Group INC | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.